ENTOD Pharma eyes sales of more than half a million strips of Macushield tabs in 2022
Macushield tablets assist with age-related macular degeneration, diabetic retinopathy and improve overall vision
ENTOD Pharmaceuticals is eyeing sales of more than half a million strips of Macushield tablets in 2022. Macushield tablets were developed by the research team of ENTOD Pharmaceuticals in early 2012, and since then have been available in both Indian and overseas markets.
“The Macushield formula has been found to be a safer and more effective ocular supplement of choice for the management of AMD and diabetic retinopathy. So far the market response has been greatly encouraging with excellent feedback from both patients and prescribing eye specialists. “The product has seen exponential growth over the years both in the domestic and overseas international markets. We expect the sale of Macushield to skyrocket in 2022 owing to a growing awareness of eye health and preventable blindness in the public,” said Nikkhil K Masurkar, Executive Director, ENTOD Pharmaceuticals.
“Age-related macular degeneration occurs mostly in those older than 55, where it progressively damages the central portion of the retina, or macula, which is responsible for the sharpest vision. Macushield tablets can be easily swallowed, are capable of stopping the destruction, and can effectively transform the leading cause of blindness among people into a chronic but controllable medical condition. It is very well accepted by ophthalmologists around the country and worldwide, helping in vision & eyesight improvement. Composed of effective lipid-soluble antioxidants and antioxidant enzymes, the relatively small size of the tablet makes it easier to swallow, thereby making it suitable and appropriate for older patients as well. Taking Macushield regularly as prescribed by your eye specialist can help to stop AMD and proliferative diabetic retinopathy in their tracks,” said Anjula Masurkar, Clinical Director, ENTOD Pharmaceuticals.
